Elekta AB ser B

sek 129.80 <%= Resources.Global.txtUp %>
Updated 13/06/2019
Change % 1.01% Stock price increasing
Change 1.30 Stock price increasing
Volume 880,991
High SEK 129.80
Low SEK 127.90
Open SEK 128.00
ISIN SE0000163628
Prev close SEK 128.50
# of shares 368.59M
Market cap 47,843M SEK

Market closed
Elekta AB ser B
Market is closed, opens at 08:00
Price development Latest 1 week 1 month 3 months 6 months 1 year
  129.80 5.2% Stock price increasing 17.9% Stock price increasing 10.1% Stock price increasing 14.5% Stock price increasing 13.8% Stock price increasing
Powered by TradingView


Latest 1 week 1 month 3 months 6 months 1 year
Competitors Open
Smith & Nephew PLC ORD USD0.20 1,703.50 0.6% Stock price increasing 3.9% Stock price increasing 15.1% Stock price increasing 14.7% Stock price increasing 24.6% Stock price increasing 16.4% Stock price increasing
Varian Medical Systems Inc 130.88 0.1% Stock price increasing 0.0% Stock price decreasing -4.2% Stock price decreasing 9.9% Stock price increasing 7.1% Stock price increasing 15.5% Stock price increasing
Cantel MED Corp DL-,10 66.57 -0.5% Stock price decreasing 12.1% Stock price increasing 13.2% Stock price increasing -4.7% Stock price decreasing -22.3% Stock price decreasing 6.2% Stock price increasing
Accuray Incorporated 3.710 3.1% Stock price increasing -5.4% Stock price decreasing -16.8% Stock price decreasing -1.9% Stock price decreasing -14.7% Stock price decreasing 8.8% Stock price increasing

Company profile

The Elekta group is an international medical technology company that develops tools and treatment planning systems for radiation therapy and radio surgery used in the treatment of cancer and brain disorders. The total market for Elekta’s clinical solutions, IT systems and services is expected to grow 5-10% annually. The company has a massive potential in under equipped growing economies, as well as an increased prevalence and incidence of cancer of aging populations in developed economies. The recent economic downturn has put pressure on hospital budgets and could expectedly reduce future health care spending and to some extent make finance for private customers less available. However, despite the crisis , Elekta has performed well and has seen increases in most regions and product areas in 2010/2011. The main growth drivers for Elekta are rising cancer rates in developed countries, and under equipped emerging countries.


Instruments Last Change  
Smith & Neph.. 1,703.50 0.6% Stock price increasing
Varian Medic.. 130.88 -0.9% Stock price decreasing
Cantel MED C.. 66.57 0.7% Stock price increasing
Accuray Inco.. 3.710 -0.3% Stock price decreasing

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
16 June 2019 18:38:02
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190527.1 - EUROWEB7 - 2019-06-16 19:38:02 - 2019-06-16 18:38:02 - 1000 - Website: OKAY